Broncus Holding Corporation’s wholly-owned subsidiary has entered into a share transfer agreement to acquire target shares in another company for a total consideration of US$15 million. The agreement was signed on December 29, 2025, with closing subject to certain conditions precedent, including the accuracy of the purchaser’s representations and warranties at closing and the fulfillment of all required obligations under the agreement. The long stop date for completion of the acquisition is March 31, 2026, unless otherwise agreed by both parties. Broncus Holding Corporation cited confidence in the business performance and prospects of the target company, particularly in the area of interventional treatment for mitral and tricuspid valves, as the rationale for the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Broncus Holding Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251229-11969638), on December 29, 2025, and is solely responsible for the information contained therein.